17 . October , 2018 - Wednesday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Fosphenytoin

Big Image
Generic Name: Fosphenytoin sodium
Dosage Form: Injection

Fosphenytoin Description

Fosphenytoin Sodium Injection, USP is a prodrug intended for parenteral administration; its active metabolite is phenytoin. Each Fosphenytoin sodium injection vial contains 75 mg/mL Fosphenytoin sodium (hereafter referred to as Fosphenytoin) equivalent to 50 mg/mL phenytoin sodium after administration. Fosphenytoin sodium injection is supplied in vials as a ready-mixed solution in Water for Injection, and Tromethamine (TRIS), buffer adjusted to pH 8.6 to 9.0 with either Hydrochloric Acid, or Sodium Hydroxide. Fosphenytoin sodium injection is a clear, colorless to pale yellow, sterile solution.

The chemical name of Fosphenytoin is 5,5-diphenyl-3-[(phosphonooxy)methyl]-2,4 imidazolidinedione disodium salt. The molecular structure of Fosphenytoin is:

The molecular weight of Fosphenytoin is 406.24.

IMPORTANT NOTE: Throughout all Fosphenytoin sodium injection product labeling, the amount and concentration of Fosphenytoin is expressed in terms of phenytoin sodium equivalents (PE). Fosphenytoin’s weight is expressed as phenytoin sodium equivalents to avoid the need to perform molecular weight-based adjustments when converting between Fosphenytoin and phenytoin sodium doses. Fosphenytoin sodium injection should always be prescribed and dispensed in phenytoin sodium equivalent units (PE) (see DOSAGE AND ADMINISTRATION).

Fosphenytoin - Clinical Pharmacology

Introduction

Following parenteral administration of Fosphenytoin sodium injection, Fosphenytoin is converted to the anticonvulsant phenytoin. For every mmol of Fosphenytoin administered, one mmol of phenytoin is produced. The pharmacological and toxicological effects of Fosphenytoin include those of phenytoin.

However, the hydrolysis of Fosphenytoin to phenytoin yields two metabolites, phosphate and formaldehyde. Formaldehyde is subsequently converted to formate, which is in turn metabolized via a folate dependent mechanism. Although phosphate and formaldehyde (formate) have potentially important biological effects, these effects typically occur at concentrations considerably in excess of those obtained when Fosphenytoin sodium injection is administered under conditions of use recommended in this labeling.

Mechanism of Action

Fosphenytoin is a prodrug of phenytoin and accordingly, its anticonvulsant effects are attributable to phenytoin.

After IV administration to mice, Fosphenytoin blocked the tonic phase of maximal electroshock seizures at doses equivalent to those effective for phenytoin. In addition to its ability to suppress maximal electroshock seizures in mice and rats, phenytoin exhibits anticonvulsant activity against kindled seizures in rats, audiogenic seizures in mice, and seizures produced by electrical stimulation of the brainstem in rats. The cellular mechanisms of phenytoin thought to be responsible for its anticonvulsant actions include modulation of voltage-dependent sodium channels of neurons, inhibition of calcium flux across neuronal membranes, modulation of voltage-dependent calcium channels of neurons, and enhancement of the sodium-potassium ATPase activity of neurons and glial cells. The modulation of sodium channels may be a primary anticonvulsant mechanism because this property is shared with several other anticonvulsants in addition to phenytoin.

Pharmacokinetics and Drug Metabolism

Fosphenytoin

Absorption/Bioavailability

Intravenous.When Fosphenytoin sodium injection is administered by IV infusion, maximum plasma Fosphenytoin concentrations are achieved at the end of the infusion. Fosphenytoin has a half-life of approximately 15 minutes.

Intramuscular.Fosphenytoin is completely bioavailable following IM administration of Fosphenytoin sodium injection. Peak concentrations occur at approximately 30 minutes postdose. Plasma Fosphenytoin concentrations following IM administration are lower but more sustained than those following IV administration due to the time required for absorption of Fosphenytoin from the injection site.

Distribution

Fosphenytoin is extensively bound (95% to 99%) to human plasma proteins, primarily albumin. Binding to plasma proteins is saturable with the result that the percent bound decreases as total Fosphenytoin concentrations increase. Fosphenytoin displaces phenytoin from protein binding sites. The volume of distribution of Fosphenytoin increases with Fosphenytoin sodium injection dose and rate, and ranges from 4.3 to 10.8 liters.

Metabolism and Elimination

The conversion half-life of Fosphenytoin to phenytoin is approximately 15 minutes. The mechanism of Fosphenytoin conversion has not been determined, but phosphatases probably play a major role. Fosphenytoin is not excreted in urine. Each mmol of Fosphenytoin is metabolized to 1 mmol of phenytoin, phosphate, and formate (see CLINICAL PHARMACOLOGY, Introduction and PRECAUTIONS, Phosphate Load).

Phenytoin (after Fosphenytoin sodium injection administration)

In general, IM administration of Fosphenytoin sodium injection generates systemic phenytoin concentrations that are similar enough to oral phenytoin sodium to allow essentially interchangeable use.

The pharmacokinetics of Fosphenytoin following IV administration of Fosphenytoin sodium injection, however, are complex, and when used in an emergency setting (eg, status epilepticus), differences in rate of availability of phenytoin could be critical. Studies have therefore empirically determined an infusion rate for Fosphenytoin sodium injection that gives a rate and extent of phenytoin systemic availability similar to that of a 50 mg/min phenytoin sodium infusion.

A dose of 15 to 20 mg PE/kg of Fosphenytoin sodium injection infused at 100 to 150 mg PE/min yields plasma free phenytoin concentrations over time that approximate those achieved when an equivalent dose of phenytoin sodium (eg, parenteral Dilantin®) is administered at 50 mg/min (see DOSAGE AND ADMINISTRATION, WARNINGS).

FIGURE 1. Mean plasma unbound phenytoin concentrations following IV administration of 1200 mg PE Fosphenytoin sodium injection infused at 100 mg PE/min (triangles) or 150 mg PE/min (squares) and 1200 mg Dilantin infused at 50 mg/min (diamonds) to healthy subjects (N = 12). Inset shows time course for the entire 96-hour sampling period.

Following administration of single IV Fosphenytoin sodium injection doses of 400 to 1200 mg PE, mean maximum total phenytoin concentrations increase in proportion to dose, but do not change appreciably with changes in infusion rate. In contrast, mean maximum unbound phenytoin concentrations increase with both dose and rate.

Absorption/Bioavailability

Fosphenytoin is completely converted to phenytoin following IV administration, with a half-life of approximately 15 minutes. Fosphenytoin is also completely converted to phenytoin following IM administration and plasma total phenytoin concentrations peak in approximately 3 hours.

Distribution

Phenytoin is highly bound to plasma proteins, primarily albumin, although to a lesser extent than Fosphenytoin. In the absence of Fosphenytoin, approximately 12% of total plasma phenytoin is unbound over the clinically relevant concentration range. However, Fosphenytoin displaces phenytoin from plasma protein binding sites. This increases the fraction of phenytoin unbound (up to 30% unbound) during the period required for conversion of Fosphenytoin to phenytoin (approximately 0.5 to 1 hour postinfusion).

Metabolism and Elimination

Phenytoin derived from administration of Fosphenytoin sodium injection is extensively metabolized in the liver and excreted in urine primarily as 5-(p-hydroxyphenyl)-5-phenylhydantoin and its glucuronide; little unchanged phenytoin (1%-5% of the Fosphenytoin sodium injection dose) is recovered in urine. Phenytoin hepatic metabolism is saturable, and following administration of single IV Fosphenytoin sodium injection doses of 400 to 1200 mg PE, total and unbound phenytoin AUC values increase disproportionately with dose. Mean total phenytoin half-life values (12.0 to 28.9 hr) following Fosphenytoin sodium injection administration at these doses are similar to those after equal doses of parenteral Dilantin and tend to be greater at higher plasma phenytoin concentrations.

Special Populations

Patients with Renal or Hepatic Disease

Due to an increased fraction of unbound phenytoin in patients with renal or hepatic disease, or in those with hypoalbuminemia, the interpretation of total phenytoin plasma concentrations should be made with caution (see DOSAGE AND ADMINISTRATION). Unbound phenytoin concentrations may be more useful in these patient populations. After IV administration of Fosphenytoin sodium injection to patients with renal and/or hepatic disease, or in those with hypoalbuminemia, Fosphenytoin clearance to phenytoin may be increased without a similar increase in phenytoin clearance. This has the potential to increase the frequency and severity of adverse events (see PRECAUTIONS).

Age

The effect of age was evaluated in patients 5 to 98 years of age. Patient age had no significant impact on Fosphenytoin pharmacokinetics. Phenytoin clearance tends to decrease with increasing age (20% less in patients over 70 years of age relative to that in patients 20-30 years of age). Phenytoin dosing requirements are highly variable and must be individualized (see DOSAGE AND ADMINISTRATION).

Gender and Race

Gender and race have no significant impact on Fosphenytoin or phenytoin pharmacokinetics.

Pediatrics

Only limited pharmacokinetic data are available in children (N=8; age 5 to 10 years). In these patients with status epilepticus who received loading doses of Fosphenytoin sodium injection, the plasma Fosphenytoin, total phenytoin, and unbound phenytoin concentration-time profiles did not signal any major differences from those in adult patients with status epilepticus receiving comparable doses.

Clinical Studies

Infusion tolerance was evaluated in clinical studies. One double-blind study assessed infusion site tolerance of equivalent loading doses (15-20 mg PE/kg) of Fosphenytoin sodium injection infused at 150 mg PE/min or phenytoin infused at 50 mg/min. The study demonstrated better local tolerance (pain and burning at the infusion site), fewer disruptions of the infusion, and a shorter infusion period for Fosphenytoin sodium injection-treated patients (Table 1).

*
Percent of patients
TABLE 1. Infusion Tolerance of Equivalent Loading Doses of IV Fosphenytoin Sodium Injection and IV Phenytoin
  IV Fosphenytoin Sodium Injection IV Phenytoin
  N=90 N=22
Local Intolerance 9%* 90%
Infusion Disrupted 21% 67%
Average Infusion Time 13 min 44 min

Fosphenytoin sodium injection-treated patients, however, experienced more systemic sensory disturbances (see PRECAUTIONS, Sensory Disturbances).

Infusion disruptions in

Recent Drug Updates at DrugIndexOnline:





Almotriptan Malate Almotriptan Malate
Pronouncation: (al-moh-TRIP-tan MAL-ate) Class: Serotonin 5-HT 1 receptor agonist Trade Names: Axert - Tablets 6.25 mg - Tablets 12.5 mg Mechanism of Action Pharmacology Selective agonist for vascular serotonin (5-HT) receptor subtype, causing vasoconstriction of cranial arteries. Pharmacokinetics more...

Alumina, Calcium Carbonate, and Sodium Bicarbonate or Alumina, Magnesium Trisilicate, and Sodium Bicarbonate Alumina, Calcium Carbonate, and Sodium Bicarbonate or Alumina, Magnesium Trisilicate, and Sodium Bicarbonate
Some commonly used brand names are: In the U.S.— Advanced Formula Di-Gel 29 Alamag 2 Alamag Plus 9 Alenic Alka 15 Alenic Alka Extra Strength 18 Alka-Mints 27 Alkets 27 Alkets Extra Strength 27 Almacone 9 Almacone II 9 AlternaGEL 21 Alu-Cap 25 Aludrox 9 Alu-Tab 25 Amitone 27 Amphojel 25 An more...

Boostrix (adolescent formulation) Boostrix (adolescent formulation)
Generic Name: diphtheria, pertussis acellular, and tetanus vaccine (DTaP, pediatric) (dif THEER ee uh, per TUS iss ay SEL yoo ler, and TET a nus) Brand Names: Boostrix (adolescent formulation), Daptacel (pediatric formulation), Infanrix (pediatric formulation), Tripedia (pediatric for more...

Eze D.S. Eze D.S.
Generic Name: chlorzoxazone (klor ZOX a zone) Brand Names: Eze D.S., Paraflex, Parafon Forte DSC, Relaxazone, Remular, Remular-S, Strifon Fort What is Eze D.S. (chlorzoxazone)? Chlorzoxazone is a muscle relaxant. It works by blocking nerve impulses (or pain sensations) that are sent to more...

galantamine galantamine
Generic Name: galantamine (ga LAN ta meen) Brand Names: Razadyne, Razadyne ER What is galantamine? Galantamine improves the function of nerve cells in the brain. It works by preventing the breakdown of a chemical called acetylcholine (ah see til KO leen). People with dementia usually ha more...

Granulderm Granulderm
Generic Name: balsam Peru, castor oil, and trypsin topical (BAL sum pe ROO, KAS tur oyl, and TRIP sin TOP ik al) Brand Names: Dermuspray, Granulderm, Granulex, Granumed, Optase, TBC, Xenaderm What is balsam Peru, castor oil, and trypsin? Balsam Peru increases blood flow to a woun more...

Mescolor Mescolor
Some commonly used brand names are: In the U.S.— AH-chew 1 D.A. Chewable 1 Dallergy 1 Dura-Vent/DA 1 Extendryl 1 Extendryl JR 1 Extendryl SR 1 Mescolor 2 OMNIhist L.A. 1 Stahist 3 Note: In November 2000, the Food and Drug Administration (FDA) issued a public health warning regarding more...

Promethazine VC w/Codeine Promethazine VC w/Codeine
Some commonly used brand names are: In the U.S.— Alka-Seltzer Plus Cold and Cough 21 Alka-Seltzer Plus Cold and Cough Medicine Liqui-Gels 34 Alka-Seltzer Plus Night-Time Cold Liqui-Gels 35 Ami-Tex LA 69 Anatuss LA 70 Benylin Expectorant 54 Bromfed-DM 17 Broncholate 68 Carbinoxamine Compou more...